Shots:
- The company reported the data from the N-MOmentum trial involves assessing Uplizna in patients with NMOSD
- The results from the N-MOmentum trial demonstrated a reduction in pain, long-term safety, and efficacy outcomes. Additional results from the new survey demonstrated NMOSD patient attitudes towards diagnosis and treatment
- Uplizna is the first FDA-approved B-cell depleter to treat adult patients with AQP4 antibody-positive NMOSD
Click here to read full press release/ article | Ref: Horizon | Image: Horizon
The post Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021 first appeared on PharmaShots.
